These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1049 related articles for article (PubMed ID: 36528035)

  • 61. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
    Baertsch MA; Schlenzka J; Mai EK; Merz M; Hillengaß J; Raab MS; Hose D; Wuchter P; Ho AD; Jauch A; Hielscher T; Kunz C; Luntz S; Klein S; Schmidt-Wolf IG; Goerner M; Schmidt-Hieber M; Reimer P; Graeven U; Fenk R; Salwender H; Scheid C; Nogai A; Haenel M; Lindemann HW; Martin H; Noppeney R; Weisel K; Goldschmidt H
    BMC Cancer; 2016 Apr; 16():290. PubMed ID: 27114074
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
    Mori Y; Takizawa J; Katsuoka Y; Takezako N; Nagafuji K; Handa H; Kuroda J; Sunami K; Kamimura T; Ogawa R; Kikushige Y; Harada M; Akashi K; Miyamoto T;
    Cancer Sci; 2024 Jun; 115(6):2002-2011. PubMed ID: 38498976
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial.
    Yong K; Martin T; Dimopoulos MA; Mikhael J; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Casca F; Macé S; Risse ML; Moreau P
    Lancet Haematol; 2024 Jul; ():. PubMed ID: 39067465
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
    Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
    Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
    Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
    Holstein SA; Jung SH; Richardson PG; Hofmeister CC; Hurd DD; Hassoun H; Giralt S; Stadtmauer EA; Weisdorf DJ; Vij R; Moreb JS; Callander NS; van Besien K; Gentile TG; Isola L; Maziarz RT; Bashey A; Landau H; Martin T; Qazilbash MH; Rodriguez C; McClune B; Schlossman RL; Smith SE; Hars V; Owzar K; Jiang C; Boyd M; Schultz C; Wilson M; Hari P; Pasquini MC; Horowitz MM; Shea TC; Devine SM; Linker C; Anderson KC; McCarthy PL
    Lancet Haematol; 2017 Sep; 4(9):e431-e442. PubMed ID: 28826616
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.
    Gregersen H; Peceliunas V; Remes K; Schjesvold F; Abildgaard N; Nahi H; Andersen NF; Vangsted AJ; Klausen TW; Helleberg C; Carlson K; Frølund UC; Axelsson P; Stromberg O; Blimark CH; Crafoord J; Tsykunova G; Eshoj HR; Waage A; Hansson M; Gulbrandsen N
    Eur J Haematol; 2022 Jan; 108(1):34-44. PubMed ID: 34536308
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
    Bal S; Landau HJ; Shah GL; Scordo M; Dahi P; Lahoud OB; Hassoun H; Hultcrantz M; Korde N; Lendvai N; Lesokhin AM; Mailankody S; Shah UA; Smith E; Devlin SM; Avecilla S; Dogan A; Roshal M; Landgren O; Giralt SA; Chung DJ
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1394-1401. PubMed ID: 32442725
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
    Sonneveld P; Dimopoulos MA; Beksac M; van der Holt B; Aquino S; Ludwig H; Zweegman S; Zander T; Zamagni E; Wester R; Hajek R; Pantani L; Dozza L; Gay F; Cafro A; De Rosa L; Morelli A; Gregersen H; Gulbrandsen N; Cornelisse P; Troia R; Oliva S; van de Velden V; Wu K; Ypma PF; Bos G; Levin MD; Pour L; Driessen C; Broijl A; Croockewit A; Minnema MC; Waage A; Hveding C; van de Donk NWCJ; Offidani M; Palumbo GA; Spencer A; Boccadoro M; Cavo M
    J Clin Oncol; 2021 Nov; 39(32):3613-3622. PubMed ID: 34520219
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
    Mateos MV; Martínez-López J; Rodriguez Otero P; González-Calle V; Gonzalez MS; Oriol A; Gutiérrez NC; Ríos-Tamayo R; Rosiñol L; Alvarez Rivas MA; Bargay J; Gonzalez-Rodriguez AP; Alegre A; Escalante F; Iñigo Rodríguez MB; De La Rubia J; Teruel AI; de Arriba F; Palomera L; Hernández MT; Lopez Jiménez J; Reinoso-Segura M; García Mateo A; Ocio EM; Paiva B; Puig N; Cedena MT; Bladé J; Lahuerta JJ; San-Miguel JF;
    J Clin Oncol; 2024 Sep; 42(27):3247-3256. PubMed ID: 39038268
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
    Rocchi S; Tacchetti P; Pantani L; Mancuso K; Rizzello I; di Giovanni Bezzi C; Scalese M; Dozza L; Marzocchi G; Martello M; Barilà G; Antonioli E; Staderini M; Buda G; Petrini M; Cea M; Quaresima M; Furlan A; Bonalumi A; Cavo M; Zamagni E
    Hematol Oncol; 2021 Feb; 39(1):41-50. PubMed ID: 33085797
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
    Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
    Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
    Roussel M; Moreau P; Hebraud B; Laribi K; Jaccard A; Dib M; Slama B; Dorvaux V; Royer B; Frenzel L; Zweegman S; Klein SK; Broijl A; Jie KS; Wang J; Vanquickelberghe V; de Boer C; Kampfenkel T; Gries KS; Fastenau J; Sonneveld P
    Lancet Haematol; 2020 Dec; 7(12):e874-e883. PubMed ID: 33242444
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
    Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
    Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
    Siegel DS; Dimopoulos MA; Ludwig H; Facon T; Goldschmidt H; Jakubowiak A; San-Miguel J; Obreja M; Blaedel J; Stewart AK
    J Clin Oncol; 2018 Mar; 36(8):728-734. PubMed ID: 29341834
    [TBL] [Abstract][Full Text] [Related]  

  • 80. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.
    Gaballa MR; Ma J; Rauf M; Bassett R; Pasvolsky O; Tanner MR; Bashir Q; Srour SA; Saini N; Ramdial J; Nieto Y; Murphy R; Rezvani K; Tang G; Lin P; Lee HC; Patel KK; Ullah MR; Kaufman GP; Manasanch EE; Kebriaei P; Thomas SK; Weber DM; Shpall EJ; Champlin RE; Orlowski RZ; Qazilbash MH
    Bone Marrow Transplant; 2022 Jul; 57(7):1142-1149. PubMed ID: 35523847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.